NCT00526474View on ClinicalTrials.gov

Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737)

PHASE3CompletedINTERVENTIONAL

Enrollment

26,449

Participants

Timeline

Start Date

September 1, 2007

Primary Completion Date

December 1, 2011

Study Completion Date

December 1, 2011

Conditions

AtherosclerosisIschemiaMyocardial InfarctionCerebrovascular AccidentPeripheral Arterial Disease

Interventions

DRUG

Vorapaxar

2.5-mg tablet daily for at least 1 year

DRUG

Placebo

matching tablet daily for at least 1 year

All Listed Sponsors

collaborator

The TIMI Study Group

OTHER

lead

Merck Sharp & Dohme LLC

INDUSTRY

NCT00526474 - Trial to Assess the Effects of Vorapaxar (SCH 530348; MK-5348) in Preventing Heart Attack and Stroke in Patients With Atherosclerosis (TRA 2°P - TIMI 50) (P04737) | Biotech Hunter | Biotech Hunter